IM Cannabis Corp. (IMCC)
Every figure this model derived for IMCC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 13,000 | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
2025-12-31 |
| cash | 2,727,000 | CashAndCashEquivalents |
2025-12-31 |
| current assets | 22,741,000 | CurrentAssets |
2025-12-31 |
| current liabilities | 34,006,000 | CurrentLiabilities |
2025-12-31 |
| equity | -3,730,000 | EquityAttributableToOwnersOfParent |
2025-12-31 |
| interest expense | 3,502,000 | FinanceCosts |
2025-12-31 |
| ocf | 4,716,000 | CashFlowsFromUsedInOperatingActivities |
2025-12-31 |
| revenue | 54,731,000 | Revenue |
2025-12-31 |
| sbc | 14,000 | ExpenseFromSharebasedPaymentTransactionsWithEmployees |
2025-12-31 |
The ratios
The figures themselves rather than their scores — what somebody looking up IMCC on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | -20.6 |
| current ratio | 0.67 |
| current ratio reported | 0.67 |
| ev owner earnings | 8.14 |
| ev sales | 0.7 |
| fcf margin | 8.59 |
| growth cv | 1.31 |
| interest cover | -3.31 |
| operating margin | -21.17 |
| owner earnings margin | 8.57 |
| revenue growth | 1.3 |
| revenue growth per share | 1.3 |
| roic | -38.92 |
| rule of 40 | -19.88 |
| sbc pct revenue | 0.03 |
Everything else this filing tags
279 more elements from IMCC's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
IssuedCapital | 270,518,000 | 2025-12-31 | 20 | CAD |
RetainedEarnings | -270,210,000 | 2025-12-31 | 20 | CAD |
EstimatedFinancialEffectOfContingentLiabilities | 261,000,000 | 2019-08-19 | 2 | CAD |
ImpairmentLoss | 115,112,000 | 2024-12-31 | 5 | CAD |
AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill | 107,854,000 | 2024-12-31 | 4 | CAD |
CostOfSales | 45,045,000 | 2025-12-31 | 32 | CAD |
CostOfMerchandiseSold | 43,351,000 | 2025-12-31 | 21 | CAD |
Liabilities | 35,351,000 | 2025-12-31 | 20 | CAD |
Assets | 31,736,000 | 2025-12-31 | 20 | CAD |
EquityAndLiabilities | 31,736,000 | 2025-12-31 | 20 | CAD |
OperatingExpense | 21,273,000 | 2025-12-31 | 32 | CAD |
ImpairmentLossRecognisedInProfitOrLossInvestmentProperty | 17,959,000 | 2022-11-07 | 3 | CAD |
OtherLiabilities | 17,334,000 | 2022-11-07 | 2 | CAD |
Borrowings | 15,269,000 | 2025-12-31 | 6 | CAD |
ShorttermBorrowings | 14,333,000 | 2025-12-31 | 20 | CAD |
ComprehensiveIncome | -14,194,000 | 2025-12-31 | 32 | CAD |
ComprehensiveIncomeAttributableToOwnersOfParent | -13,848,000 | 2025-12-31 | 32 | CAD |
LiabilitiesArisingFromFinancingActivities | 13,820,000 | 2023-12-31 | 12 | CAD |
CashFlowsFromUsedInOperatingActivitiesContinuingOperations | 13,212,000 | 2023-06-30 | 1 | CAD |
AdjustedWeightedAverageShares | 12,819,000 | 2023-12-31 | 12 | shares |
WeightedAverageShares | 12,819,000 | 2023-12-31 | 12 | shares |
TradeAndOtherCurrentPayablesToTradeSuppliers | 12,055,000 | 2025-12-31 | 20 | CAD |
ProfitLossFromContinuingOperations | -11,771,000 | 2024-12-31 | 13 | CAD |
ProfitLoss | -11,750,000 | 2025-12-31 | 32 | CAD |
AccountingProfit | -11,658,000 | 2025-12-31 | 16 | CAD |
ProfitLossBeforeTax | -11,658,000 | 2025-12-31 | 32 | CAD |
ProfitLossFromOperatingActivities | -11,587,000 | 2025-12-31 | 32 | CAD |
ProfitLossAttributableToOwnersOfParent | -11,319,000 | 2025-12-31 | 32 | CAD |
CurrentTradeReceivables | 10,848,000 | 2025-12-31 | 20 | CAD |
Borrowings | 10,500,000 | 2022-10-11 | 1 | ILS |
CostOfInventoriesRecognisedAsExpenseDuringPeriod | 10,122,000 | 2020-12-31 | 2 | CAD |
GrossProfit | 9,686,000 | 2025-12-31 | 32 | CAD |
GeneralAndAdministrativeExpense | 9,516,000 | 2025-12-31 | 32 | CAD |
NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement | 9,167,000 | 2023-12-31 | 3 | Shares |
DecreaseDueToHarvestBiologicalAssets | 9,025,000 | 2022-12-31 | 8 | CAD |
NoncurrentAssets | 8,995,000 | 2025-12-31 | 20 | CAD |
ExpenseOfRestructuringActivities | 8,791,000 | 2022-06-30 | 2 | CAD |
AdjustmentsForReconcileProfitLoss | 8,641,000 | 2025-12-31 | 24 | CAD |
IncreaseDecreaseInWorkingCapital | -7,839,000 | 2025-12-31 | 24 | CAD |
InventoryWritedown2011 | 7,228,000 | 2022-11-07 | 5 | CAD |
AcquisitiondateFairValueOfTotalConsiderationTransferred | 6,960,000 | 2022-12-31 | 1 | CAD |
IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities | -6,956,000 | 2023-12-31 | 8 | CAD |
IdentifiableAssetsAcquiredLiabilitiesAssumed | 6,494,000 | 2022-12-31 | 1 | CAD |
OtherExpenseByNature | 6,387,000 | 2025-12-31 | 6 | CAD |
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | 6,306,000 | 2020-12-31 | 2 | CAD |
CurrentTaxLiabilities | 6,280,000 | 2022-06-30 | 1 | CAD |
TradeReceivables | 6,188,000 | 2025-12-31 | 2 | CAD |
OtherCurrentLiabilities | 6,073,000 | 2025-12-31 | 6 | CAD |
GainsLossesOnExchangeDifferencesOnTranslationNetOfTax | 6,054,000 | 2023-12-31 | 3 | CAD |
NumberOfSharesIssued | 5,894,812 | 2025-12-31 | 22 | shares |
NumberOfSharesOutstanding | 5,894,812 | 2025-12-31 | 29 | shares |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | 5,390,000 | 2025-12-31 | 14 | CAD |
SalesAndMarketingExpense | 5,356,000 | 2025-12-31 | 32 | CAD |
ProceedsFromIssuingShares | 5,065,000 | 2025-12-31 | 21 | CAD |
OtherCurrentPayables | 4,486,000 | 2024-06-30 | 14 | CAD |
TradeAndOtherCurrentReceivables | 4,316,000 | 2025-12-31 | 18 | CAD |
OtherCurrentAssets | 4,316,000 | 2025-12-31 | 6 | CAD |
Inventories | 4,268,000 | 2025-12-31 | 20 | CAD |
AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | 4,058,000 | 2025-12-31 | 24 | CAD |
ReserveOfExchangeDifferencesOnTranslation | -3,842,000 | 2025-12-31 | 20 | CAD |
PropertyPlantAndEquipment | 3,711,000 | 2025-12-31 | 22 | CAD |
Equity | -3,615,000 | 2025-12-31 | 38 | CAD |
EffectOfExchangeRateChangesOnCashAndCashEquivalents | -3,467,000 | 2025-12-31 | 24 | CAD |
FinanceIncome | 3,431,000 | 2025-12-31 | 28 | CAD |
ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects | 3,296,000 | 2025-06-30 | 25 | CAD |
ProceedsFromBorrowingsClassifiedAsFinancingActivities | 3,271,000 | 2025-12-31 | 18 | CAD |
WagesAndSalaries | 3,250,000 | 2024-06-30 | 16 | CAD |
ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity | 3,173,000 | 2025-06-30 | 7 | CAD |
CurrentInvestments | 3,129,000 | 2021-12-31 | 2 | CAD |
IntangibleAssetsAndGoodwill | 3,107,000 | 2025-12-31 | 8 | CAD |
TaxExpenseIncomeAtApplicableTaxRate | -3,089,000 | 2025-12-31 | 16 | CAD |
CurrentGovernmentGrants | 2,588,000 | 2025-12-31 | 4 | CAD |
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | -2,492,000 | 2025-12-31 | 32 | CAD |
OtherComprehensiveIncome | -2,444,000 | 2025-12-31 | 32 | CAD |
CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings | -2,392,000 | 2024-06-30 | 4 | CAD |
IssueOfEquity | 2,351,000 | 2023-06-30 | 10 | CAD |
FinancialLiabilitiesAtAmortisedCost | 2,301,000 | 2025-12-31 | 1 | CAD |
ReserveOfEquityComponentOfConvertibleInstruments | 2,168,000 | 2025-12-31 | 6 | CAD |
OtherPayables | 2,114,000 | 2020-12-31 | 2 | CAD |
CurrentAdvancesToSuppliers | 2,073,000 | 2025-12-31 | 18 | CAD |
AdjustmentsForDecreaseIncreaseInOtherCurrentAssets | 2,033,000 | 2025-12-31 | 8 | CAD |
Goodwill | 1,885,000 | 2025-12-31 | 20 | CAD |
IncreaseDecreaseInCashAndCashEquivalents | 1,864,000 | 2025-12-31 | 24 | CAD |
CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations | -1,850,000 | 2022-11-06 | 7 | CAD |
RepaymentsOfBorrowingsClassifiedAsFinancingActivities | 1,810,000 | 2025-12-31 | 15 | CAD |
FinancialAssetsAtFairValueThroughProfitOrLoss | 1,776,000 | 2025-12-31 | 20 | CAD |
InvestmentsInSubsidiariesJointVenturesAndAssociates | 1,776,000 | 2025-12-31 | 5 | CAD |
AdjustmentsForIncreaseDecreaseInTradeAccountPayable | 1,738,000 | 2025-12-31 | 24 | CAD |
CurrentAccruedExpensesAndOtherCurrentLiabilities | 1,615,000 | 2023-12-31 | 8 | CAD |
ShorttermEmployeeBenefitsAccruals | 1,545,000 | 2020-12-31 | 2 | CAD |
NoncurrentLiabilities | 1,345,000 | 2025-12-31 | 20 | CAD |
AmortisationIntangibleAssetsOtherThanGoodwill | 1,338,000 | 2025-12-31 | 24 | CAD |
IntangibleAssetsOtherThanGoodwill | 1,222,000 | 2025-12-31 | 20 | CAD |
DepreciationAndAmortisationExpense | 1,191,000 | 2024-06-30 | 16 | CAD |
ProceedsFromIssuingOtherEquityInstruments | 1,154,000 | 2024-12-31 | 7 | CAD |
CashFlowsFromUsedInFinancingActivities | 1,146,000 | 2025-12-31 | 24 | CAD |
ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | 997,000 | 2025-12-31 | 1 | CAD |
DeferredTaxLiabilityAsset | 963,000 | 2023-12-31 | 8 | CAD |
IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities | 945,000 | 2019-12-31 | 1 | CAD |
CurrentPortionOfLongtermBorrowings | 936,000 | 2025-12-31 | 6 | CAD |
LongtermBorrowings | 936,000 | 2025-12-31 | 18 | CAD |
ProfessionalFeesExpense | 912,000 | 2025-12-31 | 15 | CAD |
AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables | 892,000 | 2024-06-30 | 16 | CAD |
AcquisitionsThroughBusinessCombinationsBiologicalAssets | 848,000 | 2021-12-31 | 2 | CAD |
CurrentDepositsFromCustomers | 787,000 | 2023-12-31 | 8 | CAD |
AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities | 732,000 | 2025-12-31 | 8 | CAD |
AdjustmentsForDecreaseIncreaseInBiologicalAssets | -722,000 | 2025-12-31 | 20 | CAD |
AmountsPayableRelatedPartyTransactions | 698,000 | 2025-12-31 | 10 | CAD |
EstimatedFinancialEffectOfContingentLiabilities | 686,000 | 2019-08-19 | 4 | ILS |
PurchaseOfTreasuryShares | -660,000 | 2021-12-31 | 1 | CAD |
BorrowingsRecognisedAsOfAcquisitionDate | 624,000 | 2019-12-31 | 1 | CAD |
CurrentDebtInstrumentsIssued | 622,000 | 2025-12-31 | 6 | CAD |
CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations | -615,000 | 2022-11-06 | 7 | CAD |
CurrentDerivativeFinancialLiabilities | 601,000 | 2025-12-31 | 6 | CAD |
FinancialLiabilitiesAtFairValueThroughProfitOrLoss | 601,000 | 2025-12-31 | 8 | CAD |
CurrentRestrictedCashAndCashEquivalents | 582,000 | 2025-12-31 | 12 | CAD |
RestrictedCashAndCashEquivalents | 582,000 | 2025-12-31 | 4 | CAD |
OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | 567,000 | 2025-12-31 | 16 | CAD |
CashFlowsFromUsedInInvestingActivities | -531,000 | 2025-12-31 | 24 | CAD |
CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents | -518,000 | 2025-12-31 | 8 | CAD |
ImpairmentLossRecognisedInProfitOrLossGoodwill | 495,000 | 2024-12-31 | 2 | CAD |
AdjustmentsForFinanceIncomeCost | -487,000 | 2025-12-31 | 24 | CAD |
ReserveOfSharebasedPayments | 475,000 | 2025-12-31 | 20 | CAD |
GoodwillRecognisedAsOfAcquisitionDate | 466,000 | 2022-12-31 | 2 | CAD |
UndiscountedOperatingLeasePaymentsToBeReceived | 455,000 | 2025-12-31 | 2 | CAD |
ProfitLossAttributableToNoncontrollingInterests | -431,000 | 2025-12-31 | 32 | CAD |
CurrentProvisionsForEmployeeBenefits | 423,000 | 2025-12-31 | 4 | CAD |
LiabilityAssetOfDefinedBenefitPlans | 418,000 | 2022-12-31 | 9 | CAD |
RightofuseAssets | 401,000 | 2025-12-31 | 20 | CAD |
LeaseLiabilities | 376,000 | 2025-12-31 | 8 | CAD |
IncreaseDecreaseThroughExerciseOfWarrantsEquity | 372,000 | 2025-12-31 | 9 | CAD |
IssueOfConvertibleInstruments | 364,000 | 2025-12-31 | 4 | CAD |
IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities | -361,000 | 2021-12-31 | 5 | CAD |
DeferredTaxLiabilities | 355,000 | 2025-12-31 | 20 | CAD |
ComprehensiveIncomeAttributableToNoncontrollingInterests | -346,000 | 2025-12-31 | 32 | CAD |
AdjustmentsForDecreaseIncreaseInInventories | -342,000 | 2025-06-30 | 21 | CAD |
IncreaseDecreaseThroughExerciseOfOptions | 333,000 | 2022-12-31 | 12 | CAD |
IncreaseDecreaseThroughConversionOfConvertibleInstruments | 327,000 | 2024-06-30 | 2 | CAD |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 323,000 | 2025-12-31 | 22 | CAD |
CurrentLeaseLiabilities | 322,000 | 2025-12-31 | 20 | CAD |
DepreciationRightofuseAssets | 318,000 | 2025-12-31 | 24 | CAD |
IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities | 309,000 | 2023-12-31 | 8 | CAD |
DepreciationPropertyPlantAndEquipment | 300,000 | 2025-12-31 | 24 | CAD |
CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations | -300,000 | 2022-11-06 | 7 | CAD |
GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss | -286,000 | 2025-12-31 | 6 | CAD |
DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | 278,000 | 2021-12-31 | 4 | CAD |
PaymentsInRespectOfSettlementsNetDefinedBenefitLiabilityAsset | 268,000 | 2022-12-31 | 6 | CAD |
DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate | 267,000 | 2019-12-31 | 1 | CAD |
AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | 256,000 | 2024-06-30 | 16 | CAD |
IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities | -250,000 | 2020-12-31 | 3 | CAD |
RecognisedLiabilitiesDefinedBenefitPlan | 246,000 | 2022-12-31 | 6 | CAD |
GainsOnDisposalsOfPropertyPlantAndEquipment | -235,000 | 2024-12-31 | 3 | CAD |
OtherCurrentReceivables | 214,000 | 2025-12-31 | 12 | CAD |
CurrentAdvances | 209,000 | 2025-12-31 | 4 | CAD |
AdjustmentsForInterestExpense | 203,000 | 2025-12-31 | 8 | CAD |
BenefitsPaidOrPayable | 187,000 | 2022-12-31 | 6 | CAD |
CurrentTaxExpenseIncome | 186,000 | 2025-12-31 | 16 | CAD |
IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate | 183,000 | 2022-12-31 | 2 | CAD |
ShareIssueRelatedCost | 178,000 | 2023-12-31 | 7 | CAD |
CurrentLoansAndReceivables | 177,000 | 2024-12-31 | 2 | CAD |
EmployeeBenefitsExpense | 176,000 | 2020-12-31 | 2 | CAD |
PlanAssetsAtFairValue | 172,000 | 2022-12-31 | 9 | CAD |
AdjustmentsForDeferredTaxExpense | -165,000 | 2025-12-31 | 24 | CAD |
DeferredTaxExpenseIncome | -165,000 | 2025-12-31 | 16 | CAD |
ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects | -158,000 | 2025-06-30 | 7 | CAD |
IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty | 145,000 | 2025-12-31 | 3 | CAD |
TradeAndOtherReceivables | 142,000 | 2020-12-31 | 2 | CAD |
ResearchAndDevelopmentExpense | 136,000 | 2020-12-31 | 2 | CAD |
CashTransferred | 125,000 | 2022-02-24 | 1 | CAD |
ShorttermRestructuringProvision | 117,000 | 2025-12-31 | 4 | CAD |
NoncontrollingInterests | 115,000 | 2025-12-31 | 20 | CAD |
InterestIncomeOnDebtInstrumentsHeld | -115,000 | 2024-06-30 | 2 | CAD |
OtherNoncurrentPayables | 115,000 | 2025-12-31 | 4 | CAD |
CurrentPrepaidExpenses | 114,000 | 2025-12-31 | 12 | CAD |
LossesOnDisposalsOfInvestments | 114,000 | 2022-06-30 | 2 | CAD |
DecreaseThroughWriteoffFinancialAssets | 108,000 | 2022-06-30 | 1 | CAD |
ReversalOfProvisionsForCostOfRestructuring | 108,000 | 2022-12-31 | 2 | CAD |
CashTransferred | 100,000 | 2022-02-24 | 1 | USD |
PostemploymentBenefitExpenseDefinedBenefitPlans | 93,000 | 2022-12-31 | 4 | CAD |
IncomeTaxExpenseContinuingOperations | 92,000 | 2025-12-31 | 32 | CAD |
PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate | 88,000 | 2022-12-31 | 2 | CAD |
GainsLossesOnFairValueAdjustmentAttributableToPhysicalChangesBiologicalAssets | 84,000 | 2022-12-31 | 8 | CAD |
CurrentServiceCostNetDefinedBenefitLiabilityAsset | 75,000 | 2022-12-31 | 6 | CAD |
CurrentServiceCostDefinedBenefitPlans | 75,000 | 2022-12-31 | 4 | CAD |
AdjustmentsForCurrentTaxOfPriorPeriod | 71,000 | 2025-12-31 | 16 | CAD |
FinanceIncomeCost | -71,000 | 2025-12-31 | 32 | CAD |
IncreaseDecreaseThroughNetExchangeDifferencesBiologicalAssets | 62,000 | 2022-12-31 | 8 | CAD |
NoncurrentLeaseLiabilities | 54,000 | 2025-12-31 | 20 | CAD |
IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset | -48,000 | 2022-12-31 | 6 | CAD |
OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | 48,000 | 2025-12-31 | 28 | CAD |
OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | 48,000 | 2025-12-31 | 24 | CAD |
InterestPaidClassifiedAsFinancingActivities | 41,000 | 2025-12-31 | 24 | CAD |
InterestExpenseOnLeaseLiabilities | 41,000 | 2025-12-31 | 6 | CAD |
TradeAndOtherPayablesToRelatedParties | 35,000 | 2025-12-31 | 4 | CAD |
IncomeFromSubleasingRightofuseAssets | 35,000 | 2025-12-31 | 2 | CAD |
ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity | -34,000 | 2025-06-30 | 27 | CAD |
NumberOfShareOptionsGrantedInSharebasedPaymentArrangement | 31,305 | 2024-12-31 | 15 | Shares |
NumberOfOutstandingShareOptions | 28,768 | 2025-12-31 | 26 | Shares |
NumberOfShareOptionsExercisableInSharebasedPaymentArrangement | 28,766 | 2025-12-31 | 17 | Shares |
GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset | -27,000 | 2022-12-31 | 6 | CAD |
OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | -26,000 | 2024-06-30 | 12 | CAD |
AdjustmentsForFairValueGainsLosses | 25,000 | 2024-06-30 | 4 | CAD |
InventoryRecognisedAsOfAcquisitionDate | 19,000 | 2022-12-31 | 1 | CAD |
InterestExpenseIncomeNetDefinedBenefitLiabilityAsset | 18,000 | 2022-12-31 | 6 | CAD |
InterestExpenseDefinedBenefitPlans | 18,000 | 2022-12-31 | 4 | CAD |
AdjustmentsForSharebasedPayments | 14,000 | 2025-12-31 | 24 | CAD |
IncomeTaxesPaidClassifiedAsOperatingActivities | 14,000 | 2025-12-31 | 24 | CAD |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 14,000 | 2025-12-31 | 24 | CAD |
NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement | 12,642 | 2025-12-31 | 17 | Shares |
KeyManagementPersonnelCompensationSharebasedPayment | 10,000 | 2025-12-31 | 15 | CAD |
WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 | 729 | 2025-12-31 | 17 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 | 8 | 2025-12-31 | 17 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 | 8 | 2025-12-31 | 26 | CAD/shares |
WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 | 3 | 2026-11-12 | 3 | USD/shares |
ExercisePriceShareOptionsGranted2019 | 3 | 2025-12-31 | 6 | CAD/shares |
WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 | 3 | 2024-12-31 | 15 | CAD/shares |
WeightedAverageSharePriceShareOptionsGranted2019 | 3 | 2025-12-31 | 7 | CAD/shares |
BasicEarningsLossPerShareFromContinuingOperations | -3 | 2025-12-31 | 24 | CAD/shares |
DilutedEarningsLossPerShareFromContinuingOperations | -3 | 2025-12-31 | 24 | CAD/shares |
WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 | 1 | 2021-12-31 | 3 | CAD/shares |
DescriptionOfOptionLifeShareOptionsGranted | 1 | 2025-12-31 | 5 | Year |
DescriptionOfExpectedVolatilityShareOptionsGranted | 1 | 2019-12-31 | 1 | pure |
BasicAndDilutedEarningsLossPerShare | -1 | 2020-12-31 | 2 | CAD/shares |
ProportionOfOwnershipInterestInSubsidiary | 1 | 2025-12-31 | 1 | pure |
ApplicableTaxRate | 0 | 2025-12-31 | 15 | pure |
ProportionOfVotingPowerHeldInSubsidiary | 0 | 2024-09-24 | 2 | pure |
BorrowingsInterestRate | 0 | 2022-10-11 | 1 | pure |
ActuarialAssumptionOfDiscountRates | 0 | 2022-12-31 | 6 | pure |
DilutedEarningsLossPerShare | -0 | 2025-06-30 | 27 | CAD/shares |
ActuarialAssumptionOfExpectedRatesOfSalaryIncreases | 0 | 2022-12-31 | 6 | pure |
BasicEarningsLossPerShare | -0 | 2025-06-30 | 27 | CAD/shares |
AdjustmentsForGainsLossesOnChangeInFairValueLessCostsToSellBiologicalAssets | 0 | 2024-12-31 | 17 | CAD |
AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities | 0 | 2025-12-31 | 24 | CAD |
AmountsReceivableRelatedPartyTransactions | 0 | 2023-12-31 | 8 | CAD |
BiologicalAssets | 0 | 2023-12-31 | 14 | CAD |
CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | 0 | 2023-12-31 | 11 | CAD |
CurrentBiologicalAssets | 0 | 2022-12-31 | 8 | CAD |
DeferredTaxAssets | 0 | 2023-12-31 | 12 | CAD |
DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares | 0 | 2024-06-30 | 20 | shares |
ExpectedDividendAsPercentageShareOptionsGranted | 0 | 2024-12-31 | 13 | pure |
GainsLossesOnFairValueAdjustmentBiologicalAssets | 0 | 2024-12-31 | 21 | CAD |
GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementAssets | 0 | 2025-12-31 | 24 | CAD |
InventoriesAtFairValueLessCostsToSell | 0 | 2024-12-31 | 14 | CAD |
NoncurrentRecognisedLiabilitiesDefinedBenefitPlan | 0 | 2024-12-31 | 16 | CAD |
NumberOfShareOptionsExercisedInSharebasedPaymentArrangement | 0 | 2023-12-31 | 10 | Shares |
OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | 0 | 2023-12-31 | 14 | CAD |
ProceedsFromExerciseOfOptions | 0 | 2024-12-31 | 16 | CAD |
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | 0 | 2023-12-31 | 9 | CAD |
TradeAndOtherCurrentReceivablesDueFromRelatedParties | 0 | 2023-12-31 | 8 | CAD |
WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 | 0 | 2023-12-31 | 10 | CAD/shares |
CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToOtherPartiesClassifiedAsInvestingActivities | 0 | 2024-12-31 | 15 | CAD |
DerivativeFinancialAssets | 0 | 2022-12-31 | 6 | CAD |
IndemnificationAssetsRecognisedAsOfAcquisitionDate | 0 | 2022-12-31 | 5 | CAD |
LoansAndReceivables | 0 | 2022-12-31 | 6 | CAD |
NoncurrentPayablesForPurchaseOfNoncurrentAssets | 0 | 2024-12-31 | 14 | CAD |
ProceedsFromSalesOfInvestmentProperty | 0 | 2023-12-31 | 8 | CAD |
TradeAndOtherCurrentPayablesToRelatedParties | 0 | 2024-12-31 | 8 | CAD |
TreasuryShares | 0 | 2022-12-31 | 6 | CAD |
CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | 0 | 2022-06-30 | 2 | CAD |
LossesOnDisposalsOfInvestmentProperties | 0 | 2023-06-30 | 8 | CAD |
ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | 0 | 2025-12-31 | 16 | CAD |
PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities | 0 | 2022-06-30 | 2 | CAD |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | 0 | 2024-12-31 | 9 | CAD |
BasicEarningsLossPerShareFromDiscontinuedOperations | 0 | 2024-12-31 | 13 | CAD/shares |
DilutedEarningsLossPerShareFromDiscontinuedOperations | 0 | 2024-12-31 | 13 | CAD/shares |
IncreaseDecreaseThroughDisposalOfSubsidiary | 0 | 2025-12-31 | 16 | CAD |
ProfitLossFromDiscontinuedOperations | 0 | 2024-12-31 | 13 | CAD |
AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets | 0 | 2023-06-30 | 2 | CAD |
AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | 0 | 2025-12-31 | 10 | CAD |
IncreaseDecreaseInNumberOfSharesOutstanding | 0 | 2024-06-30 | 1 | shares |
AdjustmentsForDecreaseIncreaseInLoansAndAdvances | 0 | 2025-12-31 | 6 | CAD |
AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty | 0 | 2025-12-31 | 3 | CAD |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories | 0 | 2025-12-31 | 6 | CAD |
CashAdvancesAndLoansMadeToOtherPartiesClassifiedAsInvestingActivities | 0 | 2025-12-31 | 6 | CAD |
IncreaseDecreaseThroughAcquisitionOfSubsidiary | 0 | 2025-12-31 | 3 | CAD |
PurchaseOfInterestsInAssociates | 0 | 2024-12-31 | 3 | CAD |
OtherGainsLosses | 0 | 2025-06-30 | 4 | CAD |
AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment | 0 | 2025-12-31 | 3 | CAD |
LoansReceived | 0 | 2025-12-31 | 2 | CAD |
What to be careful about
What this model itself distrusts about IMCC's figures. Written by the derivation as it ran, not added afterwards.
- revenue is annual, not TTM
- operating income is annual, not TTM
- reports in CAD and quotes in USD, so the share price is converted at 1 USD = 1.4296 CAD as at 2026-10-14. Only the price is converted: every figure from the filing is as reported, and only the multiples built on market capitalisation carry the rate
- no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
- there is no operating profit to value; valuation rests on EV/revenue (0.7x) instead
- analyst estimate not used: trailing EPS is not positive, so a growth rate would be meaningless
- durability rests on 3 of 4 inputs; not tagged: contracted coverage